Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition.

Coll RC, Hill JR, Day CJ, Zamoshnikova A, Boucher D, Massey NL, Chitty JL, Fraser JA, Jennings MP, Robertson AAB, Schroder K.

Nat Chem Biol. 2019 Jun;15(6):556-559. doi: 10.1038/s41589-019-0277-7. Epub 2019 May 13.

PMID:
31086327
2.

The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients.

Ribera J, Granada I, Morgades M, Vives S, Genescà E, González C, Nomdedeu J, Escoda L, Montesinos P, Mercadal S, Coll R, González-Campos J, Abella E, Barba P, Bermúdez A, Gil C, Tormo M, Pedreño M, Martínez-Carballeira D, Hernández-Rivas JM, Orfao A, Martínez-López J, Esteve J, Bravo P, Garcia-Guiñon A, Debén G, Moraleda JM, Queizán JA, Ortín X, Moreno MJ, Feliu E, Solé F, Ribera JM; PETHEMA Group, Spanish Society of Haematology.

Br J Haematol. 2019 Jul;186(2):263-268. doi: 10.1111/bjh.15887. Epub 2019 Mar 27.

PMID:
30916384
3.

NLRC3 Restrains Responses to a T.

Holley CL, Coll RC, Schroder K.

Immunity. 2018 Dec 18;49(6):989-991. doi: 10.1016/j.immuni.2018.12.003.

PMID:
30566886
4.

Author Correction: Mitochondrial DNA synthesis fuels NLRP3 inflammasome.

Coll RC, Holley CL, Schroder K.

Cell Res. 2018 Dec;28(12):1202. doi: 10.1038/s41422-018-0112-9.

5.

Mitochondrial DNA synthesis fuels NLRP3 activation.

Coll RC, Holley CL, Schroder K.

Cell Res. 2018 Nov;28(11):1046-1047. doi: 10.1038/s41422-018-0093-8. No abstract available. Erratum in: Cell Res. 2018 Dec;28(12):1202. Title corrected.

PMID:
30283016
6.

Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trial.

Gattermann N, Coll R, Jacobasch L, Allameddine A, Azmon A, DeBonnett L, Bruederle A, Jin J; KALLISTO study investigators.

Eur J Haematol. 2018 May 19. doi: 10.1111/ejh.13096. [Epub ahead of print]

PMID:
29777631
7.

Evidence against a role for NLRP3-driven islet inflammation in db/db mice.

Kammoun HL, Allen TL, Henstridge DC, Barre S, Coll RC, Lancaster GI, Cron L, Reibe S, Chan JY, Bensellam M, Laybutt DR, Butler MS, Robertson AAB, O'Neill LA, Cooper MA, Febbraio MA.

Mol Metab. 2018 Apr;10:66-73. doi: 10.1016/j.molmet.2018.02.001. Epub 2018 Feb 7.

8.

Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity.

Boucher D, Monteleone M, Coll RC, Chen KW, Ross CM, Teo JL, Gomez GA, Holley CL, Bierschenk D, Stacey KJ, Yap AS, Bezbradica JS, Schroder K.

J Exp Med. 2018 Mar 5;215(3):827-840. doi: 10.1084/jem.20172222. Epub 2018 Feb 6.

9.

DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features.

Palomo L, Malinverni R, Cabezón M, Xicoy B, Arnan M, Coll R, Pomares H, García O, Fuster-Tormo F, Grau J, Feliu E, Solé F, Buschbeck M, Zamora L.

Epigenetics. 2018;13(1):8-18. doi: 10.1080/15592294.2017.1405199. Epub 2018 Feb 6.

10.

Solution structure of the TLR adaptor MAL/TIRAP reveals an intact BB loop and supports MAL Cys91 glutathionylation for signaling.

Hughes MM, Lavrencic P, Coll RC, Ve T, Ryan DG, Williams NC, Menon D, Mansell A, Board PG, Mobli M, Kobe B, O'Neill LAJ.

Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):E6480-E6489. doi: 10.1073/pnas.1701868114. Epub 2017 Jul 24.

11.

Sulfonylureas as Concomitant Insulin Secretagogues and NLRP3 Inflammasome Inhibitors.

Hill JR, Coll RC, Sue N, Reid JC, Dou J, Holley CL, Pelingon R, Dickinson JB, Biden TJ, Schroder K, Cooper MA, Robertson AAB.

ChemMedChem. 2017 Sep 7;12(17):1449-1457. doi: 10.1002/cmdc.201700270. Epub 2017 Aug 4.

PMID:
28703484
12.

Contrast-Enhanced Ultrasound in Vascular Surgery: Review and Update.

Bredahl K, Mestre XM, Coll RV, Ghulam QM, Sillesen H, Eiberg J.

Ann Vasc Surg. 2017 Nov;45:287-293. doi: 10.1016/j.avsg.2017.05.032. Epub 2017 Jun 7. Review.

PMID:
28600023
13.

The intracellular chloride channel proteins CLIC1 and CLIC4 induce IL-1β transcription and activate the NLRP3 inflammasome.

Domingo-Fernández R, Coll RC, Kearney J, Breit S, O'Neill LAJ.

J Biol Chem. 2017 Jul 21;292(29):12077-12087. doi: 10.1074/jbc.M117.797126. Epub 2017 Jun 2.

14.

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF.

Blood. 2016 Dec 22;128(25):2960-2975. doi: 10.1182/blood-2016-07-730556. Epub 2016 Oct 13.

15.

Clinical translation of a mesenchymal stromal cell-based therapy developed in a large animal model and two case studies of the treatment of atrophic pseudoarthrosis.

Prat S, Gallardo-Villares S, Vives M, Carreño A, Caminal M, Oliver-Vila I, Chaverri D, Blanco M, Codinach M, Huguet P, Ramírez J, Pinto JA, Aguirre M, Coll R, Garcia-López J, Granell-Escobar F, Vives J.

J Tissue Eng Regen Med. 2018 Jan;12(1):e532-e540. doi: 10.1002/term.2323. Epub 2017 Jun 1.

PMID:
27684058
16.

Questions and controversies in innate immune research: what is the physiological role of NLRP3?

Coll RC, O'Neill L, Schroder K.

Cell Death Discov. 2016 Apr 4;2:16019. doi: 10.1038/cddiscovery.2016.19. eCollection 2016. Review.

17.

Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.

Palomo L, Garcia O, Arnan M, Xicoy B, Fuster F, Cabezón M, Coll R, Ademà V, Grau J, Jiménez MJ, Pomares H, Marcé S, Mallo M, Millá F, Alonso E, Sureda A, Gallardo D, Feliu E, Ribera JM, Solé F, Zamora L.

Oncotarget. 2016 Aug 30;7(35):57021-57035. doi: 10.18632/oncotarget.10937.

18.

T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4⁺ T cells.

Arbore G, West EE, Spolski R, Robertson AAB, Klos A, Rheinheimer C, Dutow P, Woodruff TM, Yu ZX, O'Neill LA, Coll RC, Sher A, Leonard WJ, Köhl J, Monk P, Cooper MA, Arno M, Afzali B, Lachmann HJ, Cope AP, Mayer-Barber KD, Kemper C.

Science. 2016 Jun 17;352(6292):aad1210. doi: 10.1126/science.aad1210.

19.

Sterile signals generate weaker and delayed macrophage NLRP3 inflammasome responses relative to microbial signals.

Bezbradica JS, Coll RC, Schroder K.

Cell Mol Immunol. 2017 Jan;14(1):118-126. doi: 10.1038/cmi.2016.11. Epub 2016 Mar 21.

20.

Final results of a phase I-II trial using ex vivo expanded autologous Mesenchymal Stromal Cells for the treatment of osteoarthritis of the knee confirming safety and suggesting cartilage regeneration.

Soler R, Orozco L, Munar A, Huguet M, López R, Vives J, Coll R, Codinach M, Garcia-Lopez J.

Knee. 2016 Aug;23(4):647-54. doi: 10.1016/j.knee.2015.08.013. Epub 2016 Jan 11.

PMID:
26783191
21.

Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases.

Palomo L, Xicoy B, Garcia O, Mallo M, Ademà V, Cabezón M, Arnan M, Pomares H, José Larrayoz M, José Calasanz M, Maciejewski JP, Huang D, Shih LY, Ogawa S, Cervera J, Such E, Coll R, Grau J, Solé F, Zamora L.

Am J Hematol. 2016 Feb;91(2):185-92. doi: 10.1002/ajh.24227. Epub 2015 Dec 9.

22.

GSTO1-1 modulates metabolism in macrophages activated through the LPS and TLR4 pathway.

Menon D, Coll R, O'Neill LA, Board PG.

J Cell Sci. 2015 May 15;128(10):1982-90. doi: 10.1242/jcs.167858. Epub 2015 Apr 23.

23.

Role of contrast-enhanced ultrasound arterial mapping in surgical planning for patients with critical limb ischemia.

Mestre XM, Coll RV, Villegas AR, Rico CM.

Ultrasound Med Biol. 2015 Jun;41(6):1570-6. doi: 10.1016/j.ultrasmedbio.2015.02.004. Epub 2015 Mar 23.

PMID:
25813533
24.

Supervised versus non-supervised exercise in patients with recent myocardial infarction: A propensity analysis.

Coll-Fernández R, Coll R, Muñoz-Torrero JF, Aguilar E, Ramón Álvarez L, Sahuquillo JC, Yeste M, Jiménez PE, Mujal A, Monreal M; FRENA Investigators.

Eur J Prev Cardiol. 2016 Feb;23(3):245-52. doi: 10.1177/2047487315578443. Epub 2015 Mar 23.

PMID:
25802422
25.

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.

Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS, Haneklaus M, Sutton CE, Núñez G, Latz E, Kastner DL, Mills KH, Masters SL, Schroder K, Cooper MA, O'Neill LA.

Nat Med. 2015 Mar;21(3):248-55. doi: 10.1038/nm.3806. Epub 2015 Feb 16.

26.

Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1β secretion and insulin resistance despite obesity.

Finucane OM, Lyons CL, Murphy AM, Reynolds CM, Klinger R, Healy NP, Cooke AA, Coll RC, McAllan L, Nilaweera KN, O'Reilly ME, Tierney AC, Morine MJ, Alcala-Diaz JF, Lopez-Miranda J, O'Connor DP, O'Neill LA, McGillicuddy FC, Roche HM.

Diabetes. 2015 Jun;64(6):2116-28. doi: 10.2337/db14-1098. Epub 2015 Jan 27.

27.

Body mass index, body fat, and nutritional status of patients with heart failure: The PLICA study.

Gastelurrutia P, Lupón J, de Antonio M, Zamora E, Domingo M, Urrutia A, Altimir S, Coll R, Díez C, Bayes-Genis A.

Clin Nutr. 2015 Dec;34(6):1233-8. doi: 10.1016/j.clnu.2014.12.013. Epub 2014 Dec 22.

PMID:
25573807
28.

Calreticulin mutations are not present in patients with myeloproliferative chronic myelomonocytic leukemia.

Zamora L, Germing U, Cabezón M, Schuler E, Arnan M, Marcé S, Coll R, Pomares H, Brings C, Palomo L, Schmeneau J, Gallardo D, Millá F, Feliu E, Xicoy B.

Ann Hematol. 2015 May;94(5):869-71. doi: 10.1007/s00277-014-2262-2. Epub 2014 Nov 22. No abstract available.

PMID:
25413337
29.

Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction.

Greenhill CJ, Jones GW, Nowell MA, Newton Z, Harvey AK, Moideen AN, Collins FL, Bloom AC, Coll RC, Robertson AA, Cooper MA, Rosas M, Taylor PR, O'Neill LA, Humphreys IR, Williams AS, Jones SA.

Arthritis Res Ther. 2014 Aug 30;16(4):419. doi: 10.1186/s13075-014-0419-y.

30.

Glutathione transferase omega 1 is required for the lipopolysaccharide-stimulated induction of NADPH oxidase 1 and the production of reactive oxygen species in macrophages.

Menon D, Coll R, O'Neill LA, Board PG.

Free Radic Biol Med. 2014 Aug;73:318-27. doi: 10.1016/j.freeradbiomed.2014.05.020. Epub 2014 May 27.

PMID:
24873723
31.

Fragility is a key determinant of survival in heart failure patients.

Gastelurrutia P, Lupón J, Altimir S, de Antonio M, González B, Cabanes R, Rodríguez M, Urrutia A, Domingo M, Zamora E, Díez C, Coll R, Bayes-Genis A.

Int J Cardiol. 2014 Jul 15;175(1):62-6. doi: 10.1016/j.ijcard.2014.04.237. Epub 2014 Apr 28.

PMID:
24820761
32.

Spanish guideline for COPD (GesEPOC). Update 2014.

Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Riesco JA, Trigueros JA, Piñera P, Simón A, Rodríguez-Hermosa JL, Marco E, López D, Coll R, Coll-Fernández R, Lobo MÁ, Díez J, Soriano JB, Ancochea J.

Arch Bronconeumol. 2014 Jan;50 Suppl 1:1-16. doi: 10.1016/S0300-2896(14)70070-5. No abstract available.

33.

Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.

Gugliotta L, Besses C, Griesshammer M, Harrison C, Kiladjian JJ, Coll R, Smith J, Abhyankar B, Birgegård G.

Haematologica. 2014 Apr;99(4):679-87. doi: 10.3324/haematol.2012.083097. Epub 2013 Dec 13.

34.

Soluble ST2 serum concentration and renal function in heart failure.

Bayes-Genis A, Zamora E, de Antonio M, Galán A, Vila J, Urrutia A, Díez C, Coll R, Altimir S, Lupón J.

J Card Fail. 2013 Nov;19(11):768-75. doi: 10.1016/j.cardfail.2013.09.005.

PMID:
24263122
35.

Cardiac rehabilitation and outcome in stable outpatients with recent myocardial infarction.

Coll-Fernández R, Coll R, Pascual T, Sánchez Muñoz-Torrero JF, Sahuquillo JC, Manzano L, Aguilar E, Alcala-Pedrajas JN, Alvarez LR, García-Díaz AM, Mujal A, Yeste M, Monreal M.

Arch Phys Med Rehabil. 2014 Feb;95(2):322-9. doi: 10.1016/j.apmr.2013.09.020. Epub 2013 Oct 9.

PMID:
24121084
36.

Effect of fragility on quality of life in patients with heart failure.

Gastelurrutia P, Lupón J, Altimir S, de Antonio M, González B, Cabanes R, Cano L, Urrutia A, Domingo M, Zamora E, Díez C, Coll R, Bayes-Genis A.

Am J Cardiol. 2013 Dec 1;112(11):1785-9. doi: 10.1016/j.amjcard.2013.08.002. Epub 2013 Sep 5.

PMID:
24012028
37.

Head-to-head comparison of high-sensitivity troponin T and sensitive-contemporary troponin I regarding heart failure risk stratification.

de Antonio M, Lupón J, Galán A, Vila J, Zamora E, Urrutia A, Díez C, Coll R, Altimir S, Bayes-Genis A.

Clin Chim Acta. 2013 Nov 15;426:18-24. doi: 10.1016/j.cca.2013.08.014. Epub 2013 Aug 23.

PMID:
23978483
38.

Kinetics of the CTLA-4 isoforms expression after T-lymphocyte activation and role of the promoter polymorphisms on CTLA-4 gene transcription.

Pérez-García A, Osca G, Bosch-Vizcaya A, Kelleher N, Santos NY, Rodríguez R, González Y, Roncero JM, Coll R, Serrando M, Lloveras N, Tuset E, Gallardo D.

Hum Immunol. 2013 Sep;74(9):1219-24. doi: 10.1016/j.humimm.2013.05.012. Epub 2013 Jun 10.

PMID:
23756164
39.

Renal function and short-term outcome in stable outpatients with coronary, cerebrovascular or peripheral artery disease.

Bernaudo D, Coll R, Sánchez Muñoz-Torrero JF, Pascual MT, García-Díaz AM, Alvarez LR, Monreal M; FRENA Investigators.

Atherosclerosis. 2013 Jul;229(1):258-62. doi: 10.1016/j.atherosclerosis.2013.04.029. Epub 2013 May 9.

PMID:
23714334
40.

Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments.

Haneklaus M, O'Neill LA, Coll RC.

Curr Opin Immunol. 2013 Feb;25(1):40-5. doi: 10.1016/j.coi.2012.12.004. Epub 2013 Jan 7. Review.

PMID:
23305783
41.

Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study.

Besses C, Kiladjian JJ, Griesshammer M, Gugliotta L, Harrison C, Coll R, Smith J, Abhyankar B, Birgegård G.

Leuk Res. 2013 Feb;37(2):162-8. doi: 10.1016/j.leukres.2012.11.004. Epub 2012 Nov 29.

PMID:
23199894
42.

Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.

Kiladjian JJ, Besses C, Griesshammer M, Gugliotta L, Harrison C, Coll R, Smith J, Birgegård G.

Clin Drug Investig. 2013 Jan;33(1):55-63. doi: 10.1007/s40261-012-0042-0.

43.

Predictors of outcome in stable outpatients with peripheral artery disease.

Sanclemente C, Yeste M, Suarez C, Coll R, Aguilar E, Sahuquillo JC, Lerma R, Monreal M; FRENA investigators.

Intern Emerg Med. 2014 Feb;9(1):69-77. doi: 10.1007/s11739-012-0854-1. Epub 2012 Sep 29.

PMID:
23054402
44.

Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 - 50 years) and elderly (≥ 65 years) patients with essential thrombocythemia.

Besses C, Zeller W, Alvarez-Larrán A, Coll R, Troy S, Purkayastha J, Martin P, Freitag C.

Int J Clin Pharmacol Ther. 2012 Nov;50(11):787-96. doi: 10.5414/CP201711.

PMID:
22943924
45.

Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value.

Lupón J, Gastelurrutia P, de Antonio M, González B, Cano L, Cabanes R, Urrutia A, Díez C, Coll R, Altimir S, Bayes-Genis A.

Eur J Heart Fail. 2013 Jan;15(1):103-9. doi: 10.1093/eurjhf/hfs133. Epub 2012 Aug 23.

46.

Statins in heart failure: the paradox between large randomized clinical trials and real life.

Gastelurrutia P, Lupón J, de Antonio M, Urrutia A, Díez C, Coll R, Altimir S, Bayes-Genis A.

Mayo Clin Proc. 2012 Jun;87(6):555-60. doi: 10.1016/j.mayocp.2012.02.018.

47.

Depression, antidepressants, and long-term mortality in heart failure.

Diez-Quevedo C, Lupón J, González B, Urrutia A, Cano L, Cabanes R, Altimir S, Coll R, Pascual T, de Antonio M, Bayes-Genis A.

Int J Cardiol. 2013 Aug 20;167(4):1217-25. doi: 10.1016/j.ijcard.2012.03.143. Epub 2012 Apr 14.

PMID:
22507552
48.

The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes.

Coll RC, Robertson A, Butler M, Cooper M, O'Neill LA.

PLoS One. 2011;6(12):e29539. doi: 10.1371/journal.pone.0029539. Epub 2011 Dec 22. Erratum in: PLoS One. 2013;8(2). doi:10.1371/annotation/9f221489-155d-4978-a36d-30c51853e438. PLoS One. 2013;8(7). doi:10.1371/annotation/78d328b9-2c8c-4978-84b1-7e6a0b12ada1. Robertson, Avril [added]; Butler, Mark [added]; Cooper, Matthew [added].

49.

The obesity paradox in heart failure: is etiology a key factor?

Zamora E, Lupón J, de Antonio M, Urrutia A, Coll R, Díez C, Altimir S, Bayés-Genís A.

Int J Cardiol. 2013 Jul 1;166(3):601-5. doi: 10.1016/j.ijcard.2011.11.022. Epub 2011 Dec 26.

PMID:
22204855
50.

Smoking cessation and outcome in stable outpatients with coronary, cerebrovascular, or peripheral artery disease.

Alvarez LR, Balibrea JM, Suriñach JM, Coll R, Pascual MT, Toril J, López-Jiménez L, Monreal M; FRENA Investigators.

Eur J Prev Cardiol. 2013 Jun;20(3):486-95. doi: 10.1177/1741826711426090. Epub 2011 Oct 3.

PMID:
21968571

Supplemental Content

Support Center